Organogenesis achieves primary endpoint in PuraPly study

The company states: “Organogenesis (ORGO) Holdings announced the completion of a randomized controlled trial evaluating PuraPly(R)AM plus standard of care versus SOC alone in the management of non-healing diabetic foot ulcers. The prospective, multi-center, randomized controlled trial of 170 patients evaluated the safety and efficacy of PuraPly AM plus SOC. The trial achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks, compared to SOC alone. These findings further demonstrate the clinical effectiveness of PuraPly(R)AM in the management of DFUs expanding the body of evidence supporting its use. Organogenesis plans to publish the study results soon in a peer-reviewed journal.”